North America Risk Tests
Osteoporosis Risk Test
In the U.S. today, 10 million individuals are estimated to already have the disease and about 34 million are estimated to have low bone mass, placing them at increased risk for osteoporosis. About 20% of non-Hispanic white and Asian women age 50 and older are estimated to have the disease.
What is the product?
A genetic test that identifies women who are more likely to develop spine fractures leading to a “humped back” appearance as they age. This risk assessment is based on the proprietary interleukin 1 (IL1) gene variations plus other candidate genes that have been in-licensed by Interleukin Genetics that are associated with increased bone fragility, lowered estrogen response, and altered vitamin D metabolism.
What can you do with this information?
Women who are at significantly increased risk for osteoporosis and spine fractures with age can use prevention strategies earlier in life. This test is not intended to and does not diagnose a specific disease or assess a specific health condition.
The severity of periodontitis in adults is associated with local increases in IL1β and matrix metalloproteinase (MMP). Studies show that blocking these mediators produces substantial and significant reductions in periodontal disease.
What is the product?
A medical food, which will have specific disease claims aimed at inhibiting both IL1 and MMP. This product may also include a genetic test that identifies individuals at risk for overproduction of IL1 and MMP if that is determined to be of added value.
What can you do with this information?
PerioNx will offer a natural host modulation therapy to reduce IL1 levels, and inhibit MMP activity as well as identify individuals who have a predisposition to higher IL1 and MMP activity. Clinical evidence is needed to demonstrate the combined administration of an IL1 inhibitor and an MMP inhibitor is effective in modulating relevant biomarkers.
IL1 has been shown to influence many of the mechanisms that result in detrimental skin outcomes as a result of solar-induced skin aging. IL1 plays a role in the degradation of connective tissue proteins and structure of the dermis, and has been shown experimentally to impact the degree of pigment production (skin color) by epidermal cells.
What is the product?
The first phase of this program includes a genetic test predictive of risk for deleterious skin condition(s) and formulations (topical or topical plus ingested) identified and developed using mechanistic bioassays based on the skin biology impacted by the genes included in the genetic test. A Genotype-Specific Human study model is being designed to establish the role of IL1 genetic variation in the inflammatory response of skin to UV irradiation and to identify potential target biologic mechanisms for modification of that response.
What can you do with this information?
Knowing one’s predisposition to solar-induced skin aging early can help an individual to develop a plan for risk reduction. This test is not intended to and does not diagnose a specific disease or assess a specific health condition.
The number of over-weight and obese individuals has reached explosive levels in the industrialized world. In addition, there is a tremendous demand for products and services that effectively lead to weight reduction and facilitate the maintenance of a healthy weight. Of course, much of the demand for products results from the low long-term success rate with most current weight management technologies.
What is the product?
The product concept focuses on a proprietary genetic test panel centered on variations in the perilipin gene, a major regulator of fat metabolism. Low fat metabolism, burning less fat than others, is a dominant contributor to overweight. Gene variations resulting in the overproduction of perilipin may result in a life-long tendency to be overweight.
What can you do with this information?
Knowing one’s predisposition to perilipin production early can help an individual to develop a weight management plan. This test is not intended to and does not diagnose a specific disease or assess a specific health condition.